A researcher I spoke with recently described sourcing MOTS-C the same way you’d describe buying a used car from an unfamiliar seller: the listing looks fine, the price seems reasonable, and you have absolutely no way to confirm what you’re actually getting until it’s already in your hands. That’s a fair description of where this specific compound sits right now. MOTS-C is niche enough that the market hasn’t matured the way it has for BPC-157 or TB-500, and that immaturity shows up in inconsistent documentation across suppliers.
For laboratory research use only. This article is for educational purposes and does not constitute medical advice.
MOTS-C isn’t FDA-approved for any indication, has no compounding pharmacy pathway, and doesn’t move through retail, telehealth, or wellness-clinic channels under any legitimate framework. The only channel that exists is specialized research chemical suppliers selling it strictly for laboratory research use.
MOTS-C has a documented history of sequence confusion in the marketplace, which is worth understanding before you buy. The correctly characterized sequence, MRWQEMGYIFYPRKLR, was established by Dr. Changhan David Lee’s team at the University of Southern California in 2015, and it corresponds to a specific 16-amino-acid open reading frame within the mitochondrial 12S rRNA gene (CAS 1627580-64-6). Because MOTS-C is a relatively recent discovery compared to peptides that have been in the research supply chain for decades, sequence errors and mislabeling show up more often in this category than in more established compounds.
This is exactly why a Certificate of Analysis needs to confirm identity through mass spectrometry, not just report a purity percentage. A vial can test at 99% purity and still contain the wrong 16-amino-acid sequence entirely, which is a distinction a purity number alone will never catch.
Mass spectrometry sequence confirmation, listed separately from purity data. This is the single most important check specific to MOTS-C, for the reason above.
A batch-specific Certificate of Analysis. Tied to the actual lot number on your vial, not a template reused across a catalog.
Independent lab accreditation. Some suppliers in this category test through ISO/IEC 17025-accredited laboratories, which is a meaningful, verifiable accreditation standard worth looking for specifically.
Never pre-dissolved. If a supplier offers MOTS-C already in liquid form rather than lyophilized powder, treat that as a red flag rather than a convenience. Peptide degradation begins as soon as a compound is reconstituted, and pre-dissolving before shipping can mask exactly the kind of purity loss a COA is supposed to catch.
A real, accountable business. A US-based supplier operating under actual legal jurisdiction gives you recourse if something is misrepresented. Overseas grey-market operations generally don’t.
MOTS-C is one of only two peptides encoded entirely within mitochondrial DNA, studied primarily for its activation of AMPK, the cellular energy-sensing pathway that governs glucose uptake, fatty acid oxidation, and mitochondrial biogenesis. Its research base spans insulin sensitivity, exercise physiology, and age-related metabolic decline, since documented plasma MOTS-C levels drop measurably with age. For the complete mechanism breakdown, see our MOTS-C research guide, and for how it compares to a different mitochondrial-targeting compound, see MOTS-C vs SS-31.
Our MOTS-C (10mg) is manufactured in a cGMP-certified US facility and independently third-party tested for HPLC purity, mass spectrometry identity confirmation, endotoxin, and sterility, with a batch-specific Certificate of Analysis available for every order, sold strictly as lyophilized powder.
Through specialized research chemical suppliers selling it strictly for laboratory research use. There’s no retail, pharmacy, or telehealth pathway for this compound.
MOTS-C is a comparatively recent discovery (2015), and sequence mislabeling shows up more often in the market for newer, less-established compounds. A purity percentage alone doesn’t confirm the vial contains the correct 16-amino-acid sequence, mass spectrometry identity data is needed for that.
No, and this is worth treating cautiously. MOTS-C degrades once reconstituted, so a supplier selling it pre-dissolved rather than as lyophilized powder may be masking purity loss that occurred before shipping.
Look for mass spectrometry sequence confirmation listed separately from purity data, a batch-specific COA, independent lab accreditation (ISO/IEC 17025 where stated), and a verifiable US-based business.
Yes, for laboratory research use. It’s not FDA-approved for human use. Current regulatory status for research peptides is explained here.